WO2003010150A1 - Polymorph salt of a pyridazinone derivative for the treatment of arrythmia - Google Patents
Polymorph salt of a pyridazinone derivative for the treatment of arrythmia Download PDFInfo
- Publication number
- WO2003010150A1 WO2003010150A1 PCT/HU2002/000076 HU0200076W WO03010150A1 WO 2003010150 A1 WO2003010150 A1 WO 2003010150A1 HU 0200076 W HU0200076 W HU 0200076W WO 03010150 A1 WO03010150 A1 WO 03010150A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ethyl
- dimethoxy
- chloro
- phenyl
- propylamino
- Prior art date
Links
- 206010003119 arrhythmia Diseases 0.000 title claims abstract description 9
- 150000003839 salts Chemical class 0.000 title description 8
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title description 2
- GFNWSKLPHRHAOE-WLHGVMLRSA-N (e)-but-2-enedioic acid;4-chloro-5-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propylamino]-1h-pyridazin-6-one Chemical compound OC(=O)\C=C\C(O)=O.C1=C(OC)C(OC)=CC=C1CCN(C)CCCNC1=C(Cl)C=NNC1=O GFNWSKLPHRHAOE-WLHGVMLRSA-N 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 230000006793 arrhythmia Effects 0.000 claims abstract description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000001530 fumaric acid Substances 0.000 claims description 12
- 239000012442 inert solvent Substances 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000012752 auxiliary agent Substances 0.000 claims description 5
- 239000007937 lozenge Substances 0.000 claims description 5
- -1 pilules Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000008282 halocarbons Chemical class 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 239000003586 protic polar solvent Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 description 20
- 239000013078 crystal Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 10
- UUMQGMCYAJYYQR-UHFFFAOYSA-N 4-chloro-5-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propylamino]-1h-pyridazin-6-one Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCNC1=C(Cl)C=NNC1=O UUMQGMCYAJYYQR-UHFFFAOYSA-N 0.000 description 8
- 238000009835 boiling Methods 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VJWXIRQLLGYIDI-UHFFFAOYSA-N 4,5-dichloro-1h-pyridazin-6-one Chemical compound OC1=NN=CC(Cl)=C1Cl VJWXIRQLLGYIDI-UHFFFAOYSA-N 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- JWANNLXCVGJLAS-UHFFFAOYSA-N n'-[2-(3,4-dimethoxyphenyl)ethyl]-n'-methylpropane-1,3-diamine Chemical compound COC1=CC=C(CCN(C)CCCN)C=C1OC JWANNLXCVGJLAS-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Definitions
- This invention relates to a new polymorph salt, a process for the preparation thereof, pharmaceutical compositions containing the same and the use of said polymorph salt for the treatment of arrhythmia.
- the present invention is concerned with the new crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-pheny!)-ethyi]-N-methylamino]-propyiamino]-3- -[2H]-pyridazinone fumarate, a process for the preparation thereof, pharmaceutical compositions containing the same and the use of said new polymorph for the treatment of arrhythmia.
- 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyI)-ethyl]-N-methylamino]-propylamino]-3-[2H]- -pyridazinone fumarate is a useful antiarrhythmial agent which inhibits ventrical and auricular fibrillation.
- the residual oil is subjected to chromatography on a silica column and eluted with a 9:1 :0.5 mixture of ethyl acetate, methanol and concentrated ammonium hydroxide. Fumarate is then formed from the product thus obtained.
- the salt formation step is not described in the patent specification and it is only disclosed that the fumarate salts melts at 94-96 c C.
- the present invention is based on the recognition that 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate can be prepared in crystalline form which meets the above requirements. Details of the invention
- polymorph used in the present patent specification relates to the new crystalline form I 5-chloro-4-[3- -[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]- -propylamino]-3-[2H]-pyridazinone fumarate.
- the powder diffraction pattern of the new crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl3-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate of the present invention is determined under the following conditions:
- Standard reference substance SRM 675 Mica Powder (synthetic fluorographite), Ser. No.: 981307.
- the measurement is continuous: ⁇ /2 ⁇ scan: 6.00° - 35.00° 2 ⁇ Step size: 0.04°
- a protic, dipolar aprotic or apolar solvent is used as inert solvent.
- protic solvent preferably a lower alkanol (advantageously methanol or ethanol) or water or a mixture thereof can be used.
- dipolar aprotic solvents which can be used in the process acetone, ethyl acetate, acetonitrile, dimethyl formamide, dimethyl sulfoxide or hexamethyl phosphoric triamide can be mentioned.
- a halogenated hydrocarbon preferably dichloro methane, dichloro ethane or chloroform
- methanol, ethanol, water, acetonitrile, ethyl acetate, dichloro methane a mixture of ethanol and water, a mixture of ethanol and acetonitrile, a mixture of methanol and ethyl acetate or a mixture of ethanol and dichloro methane as inert solvent.
- 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone base and fumaric acid may preferably be used in equimolar amount.
- the fumarate solution thus obtained is then slowly cooled to room temperature.
- the duration of the cooling step is 1.5-24 hours, preferably 2-5 hours.
- crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methyIamino]-propylamino]-3-[2H]-pyridazinone fumarate is precipitated, which is then isolated, preferably by means of filtration or centrifuging.
- a pharmaceutical composition comprising crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)- -ethyl]-N-methylamino]-propylamino]-3-[2H]-pyridazinone fumarate as active ingredient in admixture with inert, solid or liquid pharmaceutical carriers and/or auxiliary agent.
- compositions according to the present invention can be administered orally, parenterally, by inhalation or transdermally.
- the pharmaceutical compositions can also be administered by injection (preferably intravenously, intramuscularly, intracutantly, subcutantly, intraduodenally or intraperitoneally) or by inhalation (e.g. intranasally) or transdermally.
- compositions according to the present invention can be preferably prepared in the form of tablets, capsules, pilules, powders, lozenges, sachets, suppositories, dispersible granules, solutions, emulsions, suspensions or spray.
- compositions of the present invention can be prepared by admixing crystalline form I 5- -chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate with pharmaceutically acceptable solid or liquid carriers and/or auxiliary agents and bringing the mixture to galenic form.
- compositions of the present invention can be prepared by conventional methods of pharmaceutical industry.
- compositions according to the present invention contain usual pharmaceutical carriers and/or auxiliary agent.
- carrier e.g. magnesium carbonate, magnesium stearate, talc, saccharose, lactose, pectine, dextrine, starch, gelatine, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting wax, cocoa butter etc.
- the carrier is generally the wall of the capsule so that no additional carrier is needed.
- oral administration form the lozenge and sachet can be also mentioned. Tablets, powders, capsules, pilules, sachets and lozenges are solid forms particularly suitable for oral administration.
- Suppositories may contain low melting waxes (e.g. mixtures of fatty acid triglycerides or cocoa butter) as carrier. Suppositories can be prepared by melting the wax, homogeneously distributing the active ingredient in the melt, pouring the melt homogenous mixture into mould forms of suitable size and form, and allowing the mixture to solidify under cooling.
- low melting waxes e.g. mixtures of fatty acid triglycerides or cocoa butter
- Tablets can be prepared by admixing the active ingredient with suitable carriers in the appropriate ratio and pressing the mixture into tablets of suitable form and size.
- Powders are prepared by admixing the finely powdered active ingredient with finely powdered carriers.
- liquid pharmaceutical compositions optionally sustained release solutions, suspensions and emulsions can be mentioned.
- Aqueous solutions and aqueous propylene glycol solutions are advantageous.
- Liquid pharmaceutical compositions suitable for parenteral administration can be preferably prepared in the form of aqueous polyethylene glycol solutions.
- Aqueous solutions suitable for oral administration can be prepared by dissolving the active ingredient in water and adding suitable colouring, aromatizing, stabilizing agents and thickeners.
- Aqueous suspensions suitable for oral administration can be prepared by suspending the active ingredient in water in the presence of a viscous substance (e.g. natural or artificial gums, resins, methyl cellulose, sodium carboxymethyl cellulose or other known suspending agents).
- a viscous substance e.g. natural or artificial gums, resins, methyl cellulose, sodium carboxymethyl cellulose or other known suspending agents.
- compositions can be converted into liquid compositions immediately before use and orally administered into the organism in liquid form.
- Solutions, suspensions and emulsions can be mentioned as such liquid forms of administration which can contain in addition to the active ingredient colouring agents, aromatising agents, preservatives, buffers, artificial or natural sweeteners, dispersing agents, thickeners etc.
- compositions of the present invention are preferably prepared in dosage unit form. Such dosage units contain the desired amount of the active ingredient.
- the dosage units can be put on the market in packages which contain discrete amounts of the compositions (e.g. packed tablets, capsules, or powders in vials or ampouls).
- the term "dosage" unit relates to the capsules, tablets, lozenges, sachets per se and also to the packaging which contains the suitable number of dosage units.
- compositions of the present invention can optionally contain one or more further pharmaceutical active ingredients compatible with the crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl) ⁇ -ethyl]-N-methylamino]-propylamino]-3-[2H]-pyridazinone fumarate.
- the daily dosage of crystalline form I 5-chloro-4-[3-[N- -[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]- -propylamino]-3-[2H]-pyridazinone fumarate of the present invention depends on the circumstances of the given case (e.g. the seriousness of the illness to be treated, the condition and body weight of the patient etc.) and is determined by the physician.
- method for the treatment of arrhythmia which comprises administering to the patient in need of such treatment a pharmaceutically active amount of crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)- -ethyl]-N-methylamino]-propylamino]-3-[2H]-pyridazinone fumarate.
- the reaction mixture is heated to boiling for 10 minutes under stirring, then cooled to room temperature under stirring within 2 hours, while the solution is seeded with crystalline form I 5- -chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate.
- the suspension is stirred at room temperature for 5 hours.
- the precipitated crystals are filtered and dried at 40°C in vacuo.
- the reaction mixture is heated to boiling for 10 minutes under stirring, then cooled to room temperature within an hour under stirring, while the solution is seeded with crystalline form I 5-chloro-4-[3-[N-[2- -(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]- -3-[2H]-pyridazinone fumarate.
- the suspension thus obtained is stirred at room temperature for 5 hours.
- the precipitated crystals are filtered and dried at 40°C in vacuo.
- the reaction mixture is heated to boiling for 10 minutes under stirring, then cooled to room temperature within an hour under stirring, while the solution is seeded with crystalline form I 5-chloro-4-[3-[N- -[2-(3,4-dimethoxy-phenyl)-ethyl]-N ⁇ methylamino]- -propylamino]-3-[2H]-pyridazinone fumarate.
- the suspension thus obtained is stirred at room temperature for 5 hours.
- the precipitated crystals are filtered and dried at 40°C in vacuo.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Treating Waste Gases (AREA)
- Photoreceptors In Electrophotography (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
Abstract
The invention relates to the new crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3-[2H]-pyridazinone fumarate, a process for the preparation thereof, pharmaceutical compositions containing the same and the use of said new polymorph for the treatment of arrhythmia.
Description
POLYMORPH SALT OF A PYRIDAZINONE DERIVATIVE FOR THE TREATMENT OF ARRHYTHMIA
Field of the invention
This invention relates to a new polymorph salt, a process for the preparation thereof, pharmaceutical compositions containing the same and the use of said polymorph salt for the treatment of arrhythmia.
More particularly the present invention is concerned with the new crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-pheny!)-ethyi]-N-methylamino]-propyiamino]-3- -[2H]-pyridazinone fumarate, a process for the preparation thereof, pharmaceutical compositions containing the same and the use of said new polymorph for the treatment of arrhythmia. Technical background
It is known that 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyI)-ethyl]-N-methylamino]-propylamino]-3-[2H]- -pyridazinone fumarate is a useful antiarrhythmial agent which inhibits ventrical and auricular fibrillation.
5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethy!]-N- -methylamino]-propylamino3-3-[2H]-pyridazinone fumarate was described and characterized by physical constants (melting point) the first time in GB 2,262,526 and the corresponding HU 211 ,487. However, said patent specifications are completely silent in mentioning any crystal form or structure of the product. According to the example of GB 2,262,526 5-chloro-4- -[3-[N-[2-(3,4-dimethoxy-pheπyl)-ethyl]-N-methylamino]- -propylamino]-3-[2H]-pyridazinone fumarate is prepared as follows:
4,5-dichloro-3[2H]-pyridazinone is reacted in dioxane with N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methyl-1 ,3- -propanediamine, whereupon the reaction mixture is refluxed for 10 hours and evaporated. The residual oil is subjected to chromatography on a silica column and eluted with a 9:1 :0.5 mixture of ethyl acetate, methanol and concentrated ammonium hydroxide. Fumarate is then formed from the product thus obtained. The salt formation step is not described in the patent specification and it is only disclosed that the fumarate salts melts at 94-96cC.
In PCT patent application HU-98/00054 a new process for the preparation of 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyl)-ethyl]-N-methylamino]-propylamino]-3-[2H]- -pyridazinone base is disclosed. Although it is mentioned in this document that the base can be converted into salts by methods known per se. the preparation of no salt is specifically described.
Thus the preparation of the fumarate salt has been specifically described in a concrete manner in none of the cited references. According to our experiments it has been found that when dissolving 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyl)-ethyl]-N-methylamino]-propylamino]-3-[2H]- -pyridazinone base in hot anhydrous ethanol, adding fumaric acid to the solution and evaporating the reaction mixture in vacuo a white foamy amorphous product melting at 97-99°C is obtained. A comparison of the above melting point and the value disclosed in GB 2,262,526 indicates that according to
the process disclosed in said reference actually the amorphous product was obtained.
It is known that the processing (e.g. tabletting) of amorphous active ingredients into pharmaceutical compositions is difficult and circumstantial because amorphous substances can be filtered and dried only in a difficult manner, the scaling up is encountered with difficulties and the stability and storability of the product is not satisfactory either. Essence of the invention
It is the object of the present invention to develop a new form of 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)~ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate which has favourable tabletting properties, can be easily filtered and dried, is stable for a long period of time and can be readily stored.
The above object is solved by the present invention.
The present invention is based on the recognition that 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate can be prepared in crystalline form which meets the above requirements. Details of the invention
The term "polymorph" used in the present patent specification relates to the new crystalline form I 5-chloro-4-[3- -[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]- -propylamino]-3-[2H]-pyridazinone fumarate.
According to an aspect of the present invention there is provided crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyl)-ethyl]-N-methylamino]-propy!amino]-3-[2H]- -pyridazinone fumarate characterized by the X-ray powder diffraction pattern expressed in Table 1 and Figure 1 , measured using CuKα radiation:
Table 1
Position of diffraction lines and relative intensities (> 10 %)
The powder diffraction pattern of the new crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl3-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate of the present invention is determined under the following conditions:
Equipment: PHILIPS - XPERT PW 3710 powder diffractometer
Radiation: CuKα (λ: 1.54190L) Monochromator: graphite Exciting voltage: 40 kV Anode current: 30 Ma
Standard reference substance: SRM 675 Mica Powder (synthetic fluorographite), Ser. No.: 981307. The measurement is continuous: Θ/2Θ scan: 6.00° - 35.00° 2Θ Step size: 0.04°
Sample: surface plain, width 0.5 mm, in quartz sample holder, measured and stored at room temperature.
According to another aspect of the present invention there is provided a process for the preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate which comprises a) dissolving 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyl)-ethy!]-N-methylamino]-propylamino]-3-[2H]- -pyridazinone and fumaric acid in an inert solvent under heating, slowly cooling the solution to room temperature, and thereafter isolating the precipitated crystalline polymorph; or b) dissolving amorphous 5-chIoro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate in an inert solvent under heating, slowly cooling the solution to room temperature, and thereafter isolating the precipitated crystalline polymorph.
According to process a) 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3~ -[2H]-pyridazinone base and fumaric acid are dissolved in an inert solvent under heating, preferably under heating at reflux temperature.
According to process a) a protic, dipolar aprotic or apolar solvent is used as inert solvent. As protic solvent preferably a lower alkanol (advantageously methanol or ethanol) or water or a mixture thereof can be used. From the dipolar aprotic solvents which can be used in the process acetone, ethyl acetate, acetonitrile, dimethyl formamide, dimethyl sulfoxide or hexamethyl phosphoric triamide can be
mentioned. As apolar solvent a halogenated hydrocarbon (preferably dichloro methane, dichloro ethane or chloroform) can be used. It is preferred to use methanol, ethanol, water, acetonitrile, ethyl acetate, dichloro methane, a mixture of ethanol and water, a mixture of ethanol and acetonitrile, a mixture of methanol and ethyl acetate or a mixture of ethanol and dichloro methane as inert solvent.
In the salt formation step 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone base and fumaric acid may preferably be used in equimolar amount.
The fumarate solution thus obtained is then slowly cooled to room temperature. The duration of the cooling step is 1.5-24 hours, preferably 2-5 hours. On cooling crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methyIamino]-propylamino]-3-[2H]-pyridazinone fumarate is precipitated, which is then isolated, preferably by means of filtration or centrifuging.
According to process b) amorphous 5-chloro-4-[3-[N-[2- -(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]- -3-[2H]-pyridazinone fumarate is dissolved in an inert solvent under heating, the solution is then slowly cooled to room temperature and the precipitated crystalline polymorph is isolated. The reaction conditions (inert solvent, speed of cooling) are the same as those disclosed by process a).
According to a further aspect of the present invention there is provided a pharmaceutical composition comprising
crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)- -ethyl]-N-methylamino]-propylamino]-3-[2H]-pyridazinone fumarate as active ingredient in admixture with inert, solid or liquid pharmaceutical carriers and/or auxiliary agent.
The pharmaceutical compositions according to the present invention can be administered orally, parenterally, by inhalation or transdermally. The pharmaceutical compositions can also be administered by injection (preferably intravenously, intramuscularly, intracutantly, subcutantly, intraduodenally or intraperitoneally) or by inhalation (e.g. intranasally) or transdermally.
The pharmaceutical compositions according to the present invention can be preferably prepared in the form of tablets, capsules, pilules, powders, lozenges, sachets, suppositories, dispersible granules, solutions, emulsions, suspensions or spray.
The pharmaceutical compositions of the present invention can be prepared by admixing crystalline form I 5- -chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate with pharmaceutically acceptable solid or liquid carriers and/or auxiliary agents and bringing the mixture to galenic form.
The pharmaceutical compositions of the present invention can be prepared by conventional methods of pharmaceutical industry.
The pharmaceutical compositions according to the present invention contain usual pharmaceutical carriers and/or
auxiliary agent. As carrier e.g. magnesium carbonate, magnesium stearate, talc, saccharose, lactose, pectine, dextrine, starch, gelatine, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting wax, cocoa butter etc. can be used. In case of capsules the carrier is generally the wall of the capsule so that no additional carrier is needed. As oral administration form the lozenge and sachet can be also mentioned. Tablets, powders, capsules, pilules, sachets and lozenges are solid forms particularly suitable for oral administration.
Suppositories may contain low melting waxes (e.g. mixtures of fatty acid triglycerides or cocoa butter) as carrier. Suppositories can be prepared by melting the wax, homogeneously distributing the active ingredient in the melt, pouring the melt homogenous mixture into mould forms of suitable size and form, and allowing the mixture to solidify under cooling.
Tablets can be prepared by admixing the active ingredient with suitable carriers in the appropriate ratio and pressing the mixture into tablets of suitable form and size.
Powders are prepared by admixing the finely powdered active ingredient with finely powdered carriers.
As liquid pharmaceutical compositions optionally sustained release solutions, suspensions and emulsions can be mentioned. Aqueous solutions and aqueous propylene glycol solutions are advantageous. Liquid pharmaceutical compositions suitable for parenteral administration can be
preferably prepared in the form of aqueous polyethylene glycol solutions.
Aqueous solutions suitable for oral administration can be prepared by dissolving the active ingredient in water and adding suitable colouring, aromatizing, stabilizing agents and thickeners.
Aqueous suspensions suitable for oral administration can be prepared by suspending the active ingredient in water in the presence of a viscous substance (e.g. natural or artificial gums, resins, methyl cellulose, sodium carboxymethyl cellulose or other known suspending agents).
Another type of solid pharmaceutical compositions can be converted into liquid compositions immediately before use and orally administered into the organism in liquid form. Solutions, suspensions and emulsions can be mentioned as such liquid forms of administration which can contain in addition to the active ingredient colouring agents, aromatising agents, preservatives, buffers, artificial or natural sweeteners, dispersing agents, thickeners etc.
The pharmaceutical compositions of the present invention are preferably prepared in dosage unit form. Such dosage units contain the desired amount of the active ingredient. The dosage units can be put on the market in packages which contain discrete amounts of the compositions (e.g. packed tablets, capsules, or powders in vials or ampouls). The term "dosage" unit relates to the capsules,
tablets, lozenges, sachets per se and also to the packaging which contains the suitable number of dosage units.
The pharmaceutical compositions of the present invention can optionally contain one or more further pharmaceutical active ingredients compatible with the crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)~ -ethyl]-N-methylamino]-propylamino]-3-[2H]-pyridazinone fumarate.
The daily dosage of crystalline form I 5-chloro-4-[3-[N- -[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]- -propylamino]-3-[2H]-pyridazinone fumarate of the present invention depends on the circumstances of the given case (e.g. the seriousness of the illness to be treated, the condition and body weight of the patient etc.) and is determined by the physician.
According to a still further aspect of the present invention there is provided crystalline form I 5-chloro~4-[3-[N- -[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]- -propylamino]-3-[2H]-pyridazinone fumarate, for use as pharmaceutical active ingredient.
According to a still further aspect of the present invention there is provided the use of crystalline form I 5- -chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate for the preparation of antiarrhythmial pharmaceutical compositions.
According to a still further aspect of the present invention there is provided the use of crystalline form I 5- -chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate for the treatment of arrhythmia.
According to a still further aspect of the present invention there is provided method for the treatment of arrhythmia which comprises administering to the patient in need of such treatment a pharmaceutically active amount of crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)- -ethyl]-N-methylamino]-propylamino]-3-[2H]-pyridazinone fumarate.
Further details of the present invention are to be found in the following Examples, without limiting the scope of protection to said Examples.
Example 1
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3.4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate
To 3.8 g (0.01 mole) of 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone base at first a mixture of 30 ml of methanol and 60 ml of ethyl acetate, and thereafter 1.16 g (0.01 mole) of anhydrous fumaric acid are added. The reaction mixture is heated to boiling for 10 minutes under stirring, then cooled to room temperature within 2 hours under stirring, while the solution is seeded with crystalline form I polymorph. The suspension thus obtained is stirred at room temperature for 3 hours. The precipitated crystals are filtered and dried at 40°C in vacuo. Thus 4.22 g of crystalline form I 5-chloro-4-[3-[N-[2- -(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]- -3-[2H]-pyridazinone fumarate are obtained in the form of a white product. Yield 85 %, mp.: 177-178°C. Example 2
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3.4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate
To 3.8 g (0.01 mole) of 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone base at first a mixture of 50 ml of methanol and 10 ml of water, and thereafter 1.16 g (0.01 mole) of anhydrous fumaric acid are added. The reaction mixture is
heated to boiling for 10 minutes under stirring, then cooled to room temperature within 3 hours under stirring, while the solution is seeded with crystalline form I polymorph. The suspension thus obtained is stirred at room temperature for 4 hours. The precipitated crystals are filtered and dried at 40°C in vacuo. Thus 4.42 g of white crystalline form I 5-chloro-4-[3- -[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]- -propylamino]-3-[2H]-pyridazinone fumarate are obtained in the form of a white product. Yield 89 %, mp.: 177-178°C. Example 3
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate
To 3.8 g (0.01 mole) of 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone base at first a mixture of 5 ml of ethanol and 30 ml of water, and thereafter 1.16 g (0.01 mole) of anhydrous fumaric acid are added. The reaction mixture is heated to boiling for 10 minutes under stirring, then cooled to room temperature within an hour under stirring, while the solution is seeded with crystalline form I polymorph. The suspension thus obtained is stirred at room temperature for 8 hours. The precipitated crystals are filtered and dried at 40°C in vacuo. Thus 3.98 g of white crystalline form I 5-chloro-4-[3- -[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]- -propylamino]-3-[2H]-pyridazinone fumarate are obtained. Yield 80 %, mp.: 177-178°C.
Example 4
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate
To 3.8 g (0.01 mole) of 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethylj-N~methylaminoj-propylamino]-3- -[2H]-pyridazinone base at first 60 ml of water and thereafter 1.16 g (0.01 mole) of anhydrous fumaric acid are added. The reaction mixture is heated to boiling for 10 minutes under stirring, then cooled to room temperature under stirring within 2 hours, while the solution is seeded with crystalline form I 5- -chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate. The suspension is stirred at room temperature for 5 hours. The precipitated crystals are filtered and dried at 40°C in vacuo. Thus 3.93 g of white crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate are obtained. Yield 79 %, mp.: 177-178°C. Example 5
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3.4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylaminol-3- -[2H]-pyridazinone fumarate
To 3.8 g (0.01 mole) 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyl)-ethyl]-N-methylamino]-propy!amino]-3-[2H]- -pyridazinone base at first a mixture of 250 ml of acetonitrile and 200 ml of ethanol, and thereafter 1.16 g (0.01 mole) of
anhydrous fumaric acid are added. The reaction mixture is heated to boiling for 10 minutes under stirring, then cooled to room temperature within an hour under stirring, while the solution is seeded with crystalline form I 5-chloro-4-[3-[N-[2- -(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]- -3-[2H]-pyridazinone fumarate. The suspension thus obtained is stirred at room temperature for 5 hours. The precipitated crystals are filtered and dried at 40°C in vacuo. Thus 4.57 g of white crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyl)-ethyl]-N-methylamino]-propylamino]-3-[2H]- -pyridazinone fumarate are obtained. Yield 92 %, mp.: 177- 178°C. Example 6
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3.4- -dimethoxy-phenyO-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate
To 3.8 g (0.01 mole) of 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone base at first a mixture of 250 ml of dichloro methane and 350 ml of ethanol, and thereafter 1.16 g (0.01 mole) of anhydrous fumaric acid are added. The reaction mixture is heated to boiling for 10 minutes under stirring, then cooled to room temperature within an hour under stirring, while the solution is seeded with crystalline form I 5-chloro-4-[3-[N- -[2-(3,4-dimethoxy-phenyl)-ethyl]-N~methylamino]- -propylamino]-3-[2H]-pyridazinone fumarate. The suspension thus obtained is stirred at room temperature for 5 hours. The
precipitated crystals are filtered and dried at 40°C in vacuo.
Thus 4.08 g of white crystalline form I 5-ch!oro-4-[3-[N-[2-(3,4-
-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3-
-[2H]-pyridazinone fumarate are obtained. Yield 82 %, mp.:
177-178°C.
Example 7
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3.4-
-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3-
-[2H]-pyridazinone fumarate
3.8 g (0.01 mole) of 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyl)-ethyl]-N-methylamino]-propylamino]-3-[2H]- -pyridazinone base are dissolved in 53 ml of hot anhydrous ethanol, whereupon at 77°C 1.16 g (0.01 mole) of anhydrous fumaric acid are added. The reaction mixture is heated to boiling for 10 minutes under stirring, then cooled to room temperature within 2 hours under stirring. The precipitated crystals are filtered, washed with some ethanol and dried at 40°C in vacuo. Thus 4.86 g of white crystalline form I 5-chloro- -4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]- -propylamino]-3-[2H]-pyridazinone fumarate are obtained. Yield 97.8 %, mp.: 177-178°C. Example 8
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate
4.97 g (0.01 mole) of amorphous 5-chloro-4-[3-[N-[2- -(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-
-3-[2H]-pyridazinone fumarate are dissolved in a mixture of 30 ml of methanol and 60 ml of ethyl acetate under heating at reflux temperature. The mixture is cooled to room temperature within 2 hours under stirring. The solution is seeded with crystalline form I polymorph. The precipitated crystals are filtered and dried at 40°C in vacuo. Thus 3.53 g of white crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)- -ethyl]-N-methylamino]-propylamino]-3-[2H]-pyridazinone fumarate are obtained. Yield 71 %, mp.: 177-178°C. Example 9
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyO-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate
4.97 g (0.01 mole) of amorphous 5-chloro-4-[3-[N-[2- -(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]- -3-[2H]-pyridazinone fumarate are dissolved in a mixture of 50 ml of ethanol and 10 ml of water under heating at reflux temperature. The reaction mixture is cooled to room temperature within an hour under stirring. The solution is seeded with crystalline form I polymorph. The precipitated crystals are filtered and dried at 40°C in vacuo. Thus 4.42 g of white crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyl)-ethyl]-N-methylamino]-propylamino]-3-[2H]- -pyridazinone fumarate are obtained. Yield 89 %, mp.: 177-178°C.
Example 10
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3.4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate
4.97 g (0.01 mole) of amorphous 5-chloro-4-[3-[N-[2- -(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]- -3-[2H]-pyridazinone fumarate are dissolved in a mixture of 5 ml of ethanol and 30 ml of water under heating at reflux temperature. The mixture is cooled to room temperature within an hour under stirring. The solution is seeded with crystalline form I polymorph. The precipitated crystals are filtered and dried at 40°C in vacuo. Thus 3.98 g of white crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate are obtained. Yield 80 %, mp.: 177-178°C. Example 11
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3.4- -dimethoxy-phenylVethyl1-N-methylamino]-propylamino1-3- -[2H]-pyridazinone fumarate
4.97 g (0.01 mole) of amorphous 5-chloro-4-[3-[N-[2- -(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]- -3-[2H]-pyridazinone fumarate are dissolved in 60 ml of water under heating at reflux temperature. The mixture is cooled to room temperature within 2 hours under stirring. The solution is seeded with crystalline form I polymorph. The precipitated crystals are filtered and dried at 40°C in vacuo. Thus 3.93 g of white crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-
-phenyl)-ethyl]-N-methylamino]-propylamino]-3-[2H]-
-pyridazinone fumarate are obtained. Yield 79 %, mp.:
177-178°C.
Example 12
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3,4-
-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3-
-[2H]-pyridazinone fumarate
4.97 g (0.01 mole) of amorphous 5-chloro-4-[3-[N-[2- -(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]- -3-[2H]-pyridazinone fumarate are dissolved in a mixture of 250 ml of acetonitrile and 200 ml of ethanol under heating at reflux temperature. The mixture is cooled to room temperature within an hour under stirring. The solution is seeded with crystalline form I polymorph. The precipitated crystals are filtered and dried at 40°C in vacuo. Thus 4.57 g of white crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)- -ethyl]-N-methy!amino]-propylamino]-3-[2H]-pyridazinone fumarate are obtained. Yield 92 %, mp.: 177-178°C. Example 13
Preparation of crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenylVethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate
4.97 g (0.01 mole) of amorphous 5-chloro-4-[3-[N-[2- -(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propyIamino]- -3-[2H]-pyridazinone fumarate are dissolved in a mixture of 250 ml of dichloro methane and 350 ml of ethanol under heating at reflux temperature. The mixture is cooled to room
temperature within an hour under stirring. The solution is seeded with crystalline form I polymorph. The precipitated crystals are filtered at 40°C and dried in vacuo. Thus 4.08 g of white crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- phenyl)-ethyl]-N-methylaminoj-propyIamino]-3-[2H]- pyridazinone fumarate are obtained. Yield 82 %, mp.: 177-178°C.
Claims
1. Crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methyIamino]-propylamino]-3- -[2H]-pyridazinone fumarate characterized by the X-ray powder diffraction pattern expressed in Table 1 and Figure 1 , measured using CuKα radiation:
Table 1
Position of diffraction lines and relative intensities (> 10 %)
2. Process for the preparation of crystalline form I 5- -chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate according to Claim 1 which comprises a) dissolving 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyl)-ethyl]-N-methylamino]-propylamino]-3-[2H]- -pyridazinoπe and fumaric acid in an inert solvent under heating, slowly cooling the solution to room temperature, and thereafter isolating the precipitated crystalline polymorph; or b) dissolving amorphous 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methyIamino]-propylamino]-3- -[2H]-pyridazinone fumarate in an inert solvent under heating, slowly cooling the solution to room temperature, and thereafter isolating the precipitated crystalline polymorph.
3. Process according to Claim 2 which comprises using a protic, dipolar aprotic, or apolar solvent or a mixture thereof as inert solvent.
4. Process according to Claim 3 which comprises using a lower alkanol or water or a mixture thereof as protic solvent.
5. Process according to Claim 4 which comprises using methanol or ethanol as lower alkanol.
6. Process according to Claim 2 which comprises using acetone, ethyl acetate, acetonitrile, dimethyl formamide, dimethyl sulfoxide or hexamethyl phosphoric triamide as dipolar aprotic solvent.
7. Process according to Claim 2 which comprises using a halogenated hydrocarbon as apolar solvent.
8. Process according to Claim 7 which comprises using dichloro methane, dichloro ethane or chloroform as halogenated hydrocarbon.
9. Process according to any of Claims 2-8 which comprises using methanol, ethanol, water, acetonitrile, ethyl acetate, dichloro methane, a mixture of ethanol and water, a mixture of ethanol and acetonitrile, a mixture of methanol and ethyl acetate or a mixture of ethanol and dichloro methane as inert solvent.
10. Pharmaceutical composition comprising crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methy!amino]-propylamino]-3-[2H]-pyridazinone fumarate as active ingredient in admixture with inert, solid or liquid pharmaceutical carriers and/or auxiliary agent.
11. Pharmaceutical composition in a form to be administered orally, parenterally, transdermally or by inhalation.
12. Pharmaceutical composition according to Claim 11 in the form of tablets, capsules, pilules, powders, lozenges, sachets, suppositories, dispersible granules, solutions, emulsions, suspensions or spray.
13. Process for the preparation of pharmaceutical compositions according to Claim 10 w h i c h c o m p r i s e s admixing crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy- -phenyl)-ethyl]-N-methylamino]-propylamino]-3-[2H]- -pyridazinone fumarate with pharmaceutically acceptable solid or liquid carriers and/or auxiliary agents and bringing the mixture to galenic form.
14. Crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate, for use as pharmaceutical active ingredient.
15. Use of crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate for the preparation of antiarrhythmial pharmaceutical compositions.
16. Use of crystalline form I 5-chloro-4-[3-[N-[2-(3,4- -dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3- -[2H]-pyridazinone fumarate for the treatment of arrhythmia.
17. Method for the treatment of arrhythmia w h i c h c o m p r i s e s administering to the patient in need of such treatment a pharmaceutically active amount of crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N- -methylamino]-propylamino]-3-[2H]-pyridazinone fumarate.
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA200400222A EA200400222A1 (en) | 2001-07-26 | 2002-07-26 | POLYMORPHIC SALT OF PYRIDAZINON DERIVATIVE FOR THE TREATMENT OF ARRHYTHM |
| US10/484,621 US20040266772A1 (en) | 2001-07-26 | 2002-07-26 | Polymorph salt of a pryridazinone derivative for the treatment of arrythmia |
| JP2003515509A JP2004536868A (en) | 2001-07-26 | 2002-07-26 | Polymorphic salts of pyridazinone derivatives for the treatment of arrhythmias |
| SK54-2004A SK542004A3 (en) | 2001-07-26 | 2002-07-26 | Polymorph salt of a pyridazinone derivative for the treatment arrhythmia |
| KR10-2004-7001150A KR20040030861A (en) | 2001-07-26 | 2002-07-26 | Polymorph salt of a pyridazinone derivative for the treatment of arrhythmia |
| CA002454774A CA2454774A1 (en) | 2001-07-26 | 2002-07-26 | Polymorph salt of a pyridazinone derivative for the treatment of arrythmia |
| EP02755384A EP1417179A1 (en) | 2001-07-26 | 2002-07-26 | Polymorph salt of a pyridazinone derivative for the treatment of arrhythmia |
| IL15996702A IL159967A0 (en) | 2001-07-26 | 2002-07-26 | Polymorph salt of a pyridazinone derivative for the treatment of arrythmia |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP0103064 | 2001-07-26 | ||
| HU0103064A HUP0103064A3 (en) | 2001-07-26 | 2001-07-26 | Polymorphic form of 5-chloro-4-(3-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino]-propylamino)-3-(2h)-piridazinone fumarate, its use, process for its preparation and pharmaceutical compositions containing it |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003010150A1 true WO2003010150A1 (en) | 2003-02-06 |
Family
ID=89979563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/HU2002/000076 WO2003010150A1 (en) | 2001-07-26 | 2002-07-26 | Polymorph salt of a pyridazinone derivative for the treatment of arrythmia |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040266772A1 (en) |
| EP (1) | EP1417179A1 (en) |
| JP (1) | JP2004536868A (en) |
| KR (1) | KR20040030861A (en) |
| CN (1) | CN1545505A (en) |
| CA (1) | CA2454774A1 (en) |
| CZ (1) | CZ2004124A3 (en) |
| EA (1) | EA200400222A1 (en) |
| HU (1) | HUP0103064A3 (en) |
| IL (1) | IL159967A0 (en) |
| PL (1) | PL365483A1 (en) |
| SK (1) | SK542004A3 (en) |
| WO (1) | WO2003010150A1 (en) |
| YU (1) | YU7604A (en) |
| ZA (1) | ZA200400483B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004024158A1 (en) * | 2002-09-11 | 2004-03-25 | EGIS Gyógyszergyár Rt. | Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxy-phenyl)-ethyl]-n-methylamino]-propylamino]-3-(2h)-pyridazinone as metabolic modulator |
| WO2005034918A1 (en) * | 2003-10-10 | 2005-04-21 | EGIS Gyógyszergyár Rt. | Pellets containing a pharmaceutical ingredient |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201105537D0 (en) * | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2262526A (en) * | 1991-12-20 | 1993-06-23 | Egis Gy Gyszergyar | 3(2h)-pyridazinone derivatives |
| WO1999064402A1 (en) * | 1998-06-05 | 1999-12-16 | EGIS Gyógyszergyár Rt. | Process for the preparation of a 3(2h)-pyridazinone- 4-substituted amino- 5-chloro- derivative |
-
2001
- 2001-07-26 HU HU0103064A patent/HUP0103064A3/en unknown
-
2002
- 2002-07-26 CN CNA028162587A patent/CN1545505A/en active Pending
- 2002-07-26 YU YU7604A patent/YU7604A/en unknown
- 2002-07-26 CA CA002454774A patent/CA2454774A1/en not_active Abandoned
- 2002-07-26 JP JP2003515509A patent/JP2004536868A/en active Pending
- 2002-07-26 SK SK54-2004A patent/SK542004A3/en not_active Application Discontinuation
- 2002-07-26 PL PL02365483A patent/PL365483A1/en unknown
- 2002-07-26 EA EA200400222A patent/EA200400222A1/en unknown
- 2002-07-26 US US10/484,621 patent/US20040266772A1/en not_active Abandoned
- 2002-07-26 IL IL15996702A patent/IL159967A0/en unknown
- 2002-07-26 CZ CZ2004124A patent/CZ2004124A3/en unknown
- 2002-07-26 EP EP02755384A patent/EP1417179A1/en not_active Withdrawn
- 2002-07-26 WO PCT/HU2002/000076 patent/WO2003010150A1/en not_active Application Discontinuation
- 2002-07-26 KR KR10-2004-7001150A patent/KR20040030861A/en not_active Application Discontinuation
-
2004
- 2004-01-22 ZA ZA200400483A patent/ZA200400483B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2262526A (en) * | 1991-12-20 | 1993-06-23 | Egis Gy Gyszergyar | 3(2h)-pyridazinone derivatives |
| WO1999064402A1 (en) * | 1998-06-05 | 1999-12-16 | EGIS Gyógyszergyár Rt. | Process for the preparation of a 3(2h)-pyridazinone- 4-substituted amino- 5-chloro- derivative |
Non-Patent Citations (1)
| Title |
|---|
| PANKUCSI C. ET AL: "Eletrophysical Effects of EGIS-7229, a New Antiarrhythmic Agent, in Isolated Guinea Pig Papillary Muscle", GEN. PHARMAC., vol. 29, no. 2, 1997, pages 275 - 280, XP002217130 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004024158A1 (en) * | 2002-09-11 | 2004-03-25 | EGIS Gyógyszergyár Rt. | Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxy-phenyl)-ethyl]-n-methylamino]-propylamino]-3-(2h)-pyridazinone as metabolic modulator |
| WO2005034918A1 (en) * | 2003-10-10 | 2005-04-21 | EGIS Gyógyszergyár Rt. | Pellets containing a pharmaceutical ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| YU7604A (en) | 2006-08-17 |
| CZ2004124A3 (en) | 2004-06-16 |
| IL159967A0 (en) | 2004-06-20 |
| CN1545505A (en) | 2004-11-10 |
| EA200400222A1 (en) | 2004-12-30 |
| ZA200400483B (en) | 2005-04-22 |
| KR20040030861A (en) | 2004-04-09 |
| HUP0103064A2 (en) | 2003-02-28 |
| HUP0103064A3 (en) | 2005-06-28 |
| EP1417179A1 (en) | 2004-05-12 |
| CA2454774A1 (en) | 2003-02-06 |
| JP2004536868A (en) | 2004-12-09 |
| PL365483A1 (en) | 2005-01-10 |
| HU0103064D0 (en) | 2001-10-28 |
| SK542004A3 (en) | 2004-08-03 |
| US20040266772A1 (en) | 2004-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS626703B2 (en) | ||
| WO1999036404A1 (en) | Bisulfate salt of hiv protease inhibitor | |
| CA2304702C (en) | Oral compositions of levosimendan | |
| KR20010088795A (en) | Crystalline Forms Of EtO2C-CH2-(R)Cgl-Aze-Pab-OH | |
| JP2002518377A (en) | Arylalkanoylpyridazine | |
| US7951798B2 (en) | Polymorphs of olanzapine hydrochloride | |
| WO2003010150A1 (en) | Polymorph salt of a pyridazinone derivative for the treatment of arrythmia | |
| JP2002532470A (en) | Preparation of paroxetine maleate | |
| IE45696B1 (en) | Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid | |
| AU2002321672A1 (en) | Polymorph salt of a pyridazinone derivative for the treatment of arrythmia | |
| CA2433190C (en) | Amlodipine hemimaleate | |
| EP0703915B1 (en) | Xamoneline tartrate | |
| JPH06192228A (en) | Crystalline (r)-(-)-2-cycloheptyl-n-methylsulfonyl- (4-(2-quinolynylmethoxy)phenyl)-acetamide | |
| RU2192416C2 (en) | Method of crystallization of 1-[2-(2-naphthyl)-ethyl]-4-(3- trifluoromethylphenyl)-1,2,3,6-tetra-hydropyridine hydrochloride, prepared crystalline forms and pharmaceutical composition | |
| KR100254710B1 (en) | (r)-3-methoxy-4- 1-methyl-5-(2-methyl-4,4,4-trifluorobutylca rbamoyl)indol-3-ylmethyl -n-(2-methylsulphonyl)benzamide | |
| JPH0340025B2 (en) | ||
| EP1082304B1 (en) | NEW CRYSTALLINE POLYMORPHIC FORM OF 1-METHYL-5-p-TOLUOYLPYRROLE-2-ACETAMIDOACETIC ACID GUAIACYL ESTER (MED 15) | |
| WO2003042161A1 (en) | Venlafaxine hydrochloride polymorphs | |
| US6005115A (en) | Forms A and B of N-[[[2-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl ]thio]ethyl]ami no]methylene]-4-bromo-benzenesulfonamide | |
| JPS6316385B2 (en) | ||
| JPS6122068A (en) | Oxyindole derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: P-76/04 Country of ref document: YU |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 159967 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 542004 Country of ref document: SK |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PV2004-124 Country of ref document: CZ Ref document number: 2004/00483 Country of ref document: ZA Ref document number: 200400483 Country of ref document: ZA Ref document number: 2454774 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003515509 Country of ref document: JP Ref document number: 1020047001150 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002321672 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 20028162587 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200400222 Country of ref document: EA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002755384 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10484621 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002755384 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWP | Wipo information: published in national office |
Ref document number: PV2004-124 Country of ref document: CZ |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2002755384 Country of ref document: EP |
|
| WWR | Wipo information: refused in national office |
Ref document number: PV2004-124 Country of ref document: CZ |